# Pendulum Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pendulum-therapeutics

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.pendulumlife.com
- Total disclosed funding: $119M
- Latest round: Series C (Apr 7, 2021)
- Investors on record: 8

## About

Pendulum Therapeutics, Inc. focuses on developing next-generation probiotics aimed at enhancing gut health and metabolic functions, particularly for individuals with type 2 diabetes.Pendulum Therapeutics, Inc. specializes in innovative probiotic solutions for gut health and metabolic support. Founded in 2013 in San Francisco, US, by Colleen Cutcliffe, James Bullard, and John Eid, the company has completed a total of 6 deals. The latest funding round, which raised USD 10 mn on June 30, 2023, will support product development and innovation.Pendulum primarily offers a range of next-generation probiotics designed to promote gut health and improve metabolic functions. Their flagship product, Glucose Control, is clinically shown to enhance A1C levels in individuals with type 2 diabetes, distinguishing itself as the only medical probiotic with such evidence. Other core offerings include Metabolic Daily, which aims to boost metabolism, and Akkermansia, which replenishes important gut strains. These products are designed for varying end users, including individuals managing diabetes and those seeking to improve their overall gut health. Pendulum’s products are available in various markets, including the United States, Canada, and select countries in Europe, targeting both direct consumers and healthcare professionals.Pendulum generates revenue through a subscription-based model, where customers can opt for recurring deliveries of their products, ensuring a steady supply for ongoing health management. The typical transaction structure involves direct-to-consumer sales via their online platform, allowing for easy access and order management. Pricing plans reflect the membership structure, with products like Metabolic Daily priced competitively to appeal to both individual users and healthcare providers. Customers can choose from various subscription options, such as monthly or quarterly deliveries, which encourage long-term engagement with the products. The company also explores partnerships with healthcare professionals to integrate their probiotics into patient care, further enhancing their market reach and revenue potential.Pendulum Therapeutics, Inc. aims to leverage the USD 10 mn raised in February 2023 to further develop and innovate its product lines. Plans include launching new probiotics tailored to specific metabolic health needs and expanding into additional international markets, with a strong focus on Europe and Asia. The company intends to release new products by the end of 2024, aligning with their growth strategy to broaden their customer base.

## Funding rounds

- Series C, Apr 7, 2021, $54M — Meritech Capital Partners, Hong Shan, Khosla Ventures, True Ventures
- Series B, May 30, 2019, $35M — Hong Shan, Khosla Ventures, True Ventures, Mayo Pension Plan, AME Cloud Ventures
- Series A, Jun 27, 2017, $19M — Khosla Ventures, True Ventures, Morgan Noble
- Series A, Jan 25, 2016, $8M — Hong Shan, Khosla Ventures, True Ventures, AME Cloud Ventures
- Seed, Dec 4, 2014, $3.4M — True Ventures, Felicis Ventures

## Investors

- True Ventures (https://capitalatlas.ai/funds/true-ventures) — Seed, Series A, Series B, Series C
- Felicis Ventures (https://capitalatlas.ai/funds/felicis-ventures) — Seed
- Hong Shan — Series A, Series B, Series C
- Khosla Ventures (https://capitalatlas.ai/funds/khosla-ventures) — Series A, Series B, Series C
- AME Cloud Ventures (https://capitalatlas.ai/funds/ame-cloud-ventures) — Series A, Series B
- Morgan Noble (https://capitalatlas.ai/funds/morgan-noble) — Series A
- Mayo Pension Plan — Series B
- Meritech Capital Partners (https://capitalatlas.ai/funds/meritech-capital-partners) — Series C